rockin'robin
Well-Known Member
- Joined
- Apr 22, 2007
- Messages
- 24,431
- Reaction score
- 549
Turing Pharmaceutical chief executive officer Martin Shkreli has been arrested by the FBI following an investigation involving his former hedge fund and another pharmaceutical company he recently headed.
Shkreli, 32, was seen being taken into custody by the FBI at his Murray Hill Tower Apartments in New York City earlier this morning, Reuters reported. His former counsel, Evan Greebal, was also arrested, FBI spokeswoman Kelly Langmesser confirmed.
Shkreli made headlines in September when he jacked up the price of a drug called Daraprim from $13.50 a pill to $750 overnight, CNNMoney reported. The pill is used to treat AIDS patients.
The controversy launched an investigation by the New York State attorney general for antitrust concerns.
A separate investigation of Shkreli’s time as manager of hedge fund MSMB Capital Management and CEO of biopharmaceutical company Retrophin Inc was also in the works.
According to sources close to the investigation, Shkreli is accused of using Retrophin assets to pay off debts after MSMB lost millions of dollars.
Retrophin, which was founded in 2012, sued Shkreli in August for $65 million, alleging that Shkreli used his control over the company to enrich himself and pay debts he owed to MSMB, which closed that same year. He was fired from Retrophin in September 2014.
Shkreli was also accused of defrauded MSMB. He denies the allegations.
Brooklyn U.S. Attorney Robert Capers will hold a press conference with the Federal Bureau of Investigation and U.S. Securities Exchange Commission to formally announce the charges at noon.
http://www.opposingviews.com/i/society/ceo-who-jacked-price-aids-pill-1350-750-arrested?fb=pv
Shkreli, 32, was seen being taken into custody by the FBI at his Murray Hill Tower Apartments in New York City earlier this morning, Reuters reported. His former counsel, Evan Greebal, was also arrested, FBI spokeswoman Kelly Langmesser confirmed.
Shkreli made headlines in September when he jacked up the price of a drug called Daraprim from $13.50 a pill to $750 overnight, CNNMoney reported. The pill is used to treat AIDS patients.
The controversy launched an investigation by the New York State attorney general for antitrust concerns.
A separate investigation of Shkreli’s time as manager of hedge fund MSMB Capital Management and CEO of biopharmaceutical company Retrophin Inc was also in the works.
According to sources close to the investigation, Shkreli is accused of using Retrophin assets to pay off debts after MSMB lost millions of dollars.
Retrophin, which was founded in 2012, sued Shkreli in August for $65 million, alleging that Shkreli used his control over the company to enrich himself and pay debts he owed to MSMB, which closed that same year. He was fired from Retrophin in September 2014.
Shkreli was also accused of defrauded MSMB. He denies the allegations.
Brooklyn U.S. Attorney Robert Capers will hold a press conference with the Federal Bureau of Investigation and U.S. Securities Exchange Commission to formally announce the charges at noon.
http://www.opposingviews.com/i/society/ceo-who-jacked-price-aids-pill-1350-750-arrested?fb=pv